erlotinib hydrochloride has been researched along with calpain in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (calpain) | Trials (calpain) | Recent Studies (post-2010) (calpain) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 7,019 | 25 | 2,422 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Liu, F; Lu, T; Tang, J | 1 |
1 other study(ies) available for erlotinib hydrochloride and calpain
| Article | Year |
|---|---|
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calpain; Case-Control Studies; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proto-Oncogene Proteins c-met; Survival Rate; Tumor Cells, Cultured | 2020 |